Annovis Bio Reports Promising Phase III Study Results for Buntanetap in Parkinson’s Disease Treatment

Annovis Bio, Buntanetap, Parkinson’s Disease, Phase III Study, Neurodegenerative Disorders, Cognitive Function, Motor Functions, Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)

Syntis Bio Launches Revolutionary Oral Therapy to Mimic Weight-Loss Surgery

Syntis Bio, weight-loss surgery, oral therapy, obesity, diabetes, rare diseases, SYNT-101, gastric bypass surgery, small intestine, metabolic control, digestion, drug absorption.

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis